60 Degrees Pharmaceuticals, Inc. Reports Results from Expanded Access Babesiosis Study

60 Degrees Pharmaceuticals announced clinical and molecular results for the first five patients to complete treatment with tafenoquine-containing combination regimens in its expanded access study of relapsing babesiosis in immunosuppressed patients. The provided article text ends before describing the results, so their direction and significance cannot be assessed.